17,261 trials
Extragonadal Germ Cell Tumor · Ovarian Cancer · Testicular Germ Cell Tumor
Primary: Overall Objective Response — 50; 4; 36; 8 participants
Non-Squamous Non-Small Cell Lung Cancer
Primary: Percentage of Participants With Erlotinib Associated Rash Stratified by Severity Grade at Week 2 — 11; 22; 0; 33 percentage of participants
Acute Myocardial Infarction · Heart Failure
Primary: Difference Between the Anakinra Arm and the Placebo Arm in Change in Left Ventricular End-systolic Volume Indices — 1.5; 1.0 mL/m2 — p=<0.05
Bladder Urothelial Carcinoma · Stage I Bladder Cancer AJCC v6 and v7 · Stage II Bladder Cancer AJCC v6 and v7
Primary: Acute Treatment-related Toxicity — 7; 14 participants
Prostate Cancer
Primary: Percentage of Participants With Prostate-specific Antigen (PSA) Response — 42.7 Percentage of participants
Hormone-Resistant Prostate Cancer · Metastatic Prostate Carcinoma · Recurrent Prostate Carcinoma
Primary: Change in Immune Response Assessed by IFN-g ELISPOT Specific for PA2024
Allergic Conjunctivitis
Primary: Ocular Itching — 1.27; 1.57; 1.16; 1.88 units on a scale
Acute Leukemias
Primary: Rate of Complete Remission (CR) — 0; 0 Participants
Idiopathic Pulmonary Fibrosis
Primary: Percentage of Participants With Dose Reductions — 5; 4.8 percentage of participants
Diabetes, Gestational
Primary: Correlation Between Glucose AUC and Birth Weight. — 0.2902; 0.2935; 0.2915; 0.2859 correlation coefficient — p=0.035
Non-small Cell Lung Cancer Metastatic
Primary: Time to Disease Progression — 15 weeks
Age-related Macular Degeneration · Diabetic Macular Edema · Retinal Vein Occlusion
Primary: Serum Pharmacokinetics Following Treatment From 1st and 3rd Doses — 0.45; 0.76; 0.11; 0.58 nM
Myelodysplastic Syndrome
Primary: Changes in Neutrophil Counts — -0.3 cells/mm^3
Alcoholism
Primary: Craving to Drink — 36.5; 42.9 units on a scale — p=.003
Acute Cerebral Stroke Within 12 Hours for the First Time
Primary: National Institutes of Health Stroke Scale Score — 8.78; 7.80; 8.85; 5.48 units on a scale